Диссертация (1139510), страница 54
Текст из файла (страница 54)
2014:1–14.241. Medicines used in Mental Health, Years 2004/05 - 2014/15.http://www.isdscotland.org/Health-Topics/Prescribing-andMedicines/Publications/index.asp.242. Merikangas KR, Zhang H, Avenevoli S et al. Longitudinal trajectories ofdepression and anxiety in a prospective community study: the Zurich CohortStudy. Arch Gen Psychiatry 2003;60:993–1000.243. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT2Areceptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry2001;158:78-85.244.
Milaneschi Y., Lamers F., Peyrot W.J., Abdellaoui A., Willemsen G.,Hottenga J.J. Polygenic dissection of major depression clinical heterogeneity. MolPsychiatry. 2015;21:516–522.245. Millan MJ. On ‘polypharmacy’ and multi-target agents, complementarystrategies for improving the treatment of depression: a comparative appraisal. Int JNeuropsychoph. 2014; 17(4): 1009-1037. doi: http://dx.doi.org/10.1017/S1461145712001496246. Miller A.H..Maletic V., Raison C.L.
Inflammation and its discontents: therole of cytokines in the pathophysiology of major depression. Biol Psychiatry2009; 65: 732—741.247. Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, AlpertJE. Anemia and macrocytosis in the prediction of serum folate and vitamin B12status, and treatment outcome in major depression. J Psychosomat Res.2000;49:183-187.287248.
Mocking RJT, Figueroa CA, Rive MM, et al. Vulnerability for new episodesin recurrent major depressive disorder: protocol for the longitudinal DELTAneuroimaging cohort study. BMJ Open. 2016;6(3):e009510.249. Monroe SM, Harkness KL. Recurrence in major depression: a conceptualanalysis. Psychol Rev 2011;118:655–74.250.
Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox:implications in the management of depression and anxiety. Neuropsychiatr DisTreat (2016) 12:541–57.251. Moore M, Yuen HM, Dunn N, Mullee MA, Maskell J, et al. Explaining therise in antidepressant prescribing: a descriptive study using the general practiceresearch database. BMJ. 2009;339:b3999. doi: 10.1136/bmj.b3999.252. Moore TJ, Mattison DR.
Adult utilization of psychiatric drugs anddifferences by sex, age, and race. JAMA Intern Med. 2017;177:274–275. doi:10.1001/jamainternmed.2016.7507.253. Morley S, Williams AC, Black S. A confirmatory factor analysis of the BeckDepression Inventory in chronic pain. Pain. 2002 Sep;99(1-2):289-98.254.
Mueller TI, Leon AC, Keller MB et al. Recurrence after recovery frommajor depressive disorder during 15 years of observational follow-up. Am JPsychiatry 1999;156:1000–6.255. Mullins N, Lewis CM. Genetics of Depression: Progress at Last.
CurrPsychiatry Rep (2017) 19: 43256. Mynors-Wallis L, Gath D. Predictors of treatment outcome for majordepression in primary care. Psychol Med. 1997;27:731-736.257. Myung W, Song J, Lim S-W, Won H-H, Kim S, Lee Y, et al. Geneticassociation study of individual symptoms in depression.
Psychiatry Res.2012;198:400–6.258. National Collaborating Centre for Mental Health (UK). Depression: TheTreatment and Management of Depression in Adults (Updated Edition). Leicester(UK): British Psychological Society; 2010. (NICE Clinical Guidelines, No. 90.) 9,INTRODUCTIONTOPHARMACOLOGICALANDPHYSICALINTERVENTIONS.Availablefrom:https://www.ncbi.nlm.nih.gov/books/NBK63741/259. National Guideline Clearinghouse (NGC). Guideline summary: Practiceguideline for the treatment of patients with major depressive disorder, third edition.In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agencyfor Healthcare Research and Quality (AHRQ); 2010 Oct 01. https://guideline.gov.260.
Nelson JC, Mazure CM, Jatlow PI, Bowers Jr. MB, Price LH. Combiningnorepinephrine and serotonin reuptake inhibition mechanisms for treatment of288depression: a double-blind, randomized study. Biol Psychiatry. 2004; 55: 296-300.doi: http://dx.doi.org/10.1016/ j.biopsych.2003.08.007261. Nelson JC, Papakostas GI.
Atypical antipsychotic augmentation in majordepressive disorder: a meta-analysis of placebo-controlled randomized trials. Am JPsychiatry 2009; 166: 980–991.262. Newman JR, Ewing SE, McColl RD, et al. Tridimensional personalityquestionnaire and treatment response in major depressive disorder: a negativestudy. J Affect Disord. 2000;57:241-247.263. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset ofantidepressant response with fluoxetine treatment. Am J Psychiatry.2000;157:1423-1428.264. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF,Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome.Am J Psychiatry.
1995;152:1500-1503.265. Nierenberg, A., Trivedi, M. H., Fava, M., Biggs, M. M., Shores-Wilson, K.,Wisniewski, S. R., Rush, A. J. (2007). Family history of mood disorder andcharacteristics of major depressive disorder: a STAR*D (sequenced treatmentalternatives to relieve depression) study. Journal of psychiatric research, 41(3-4),214–21.266.
Nikisch G, Eap CB, Baumann P.Citalopram enantiomers in plasma andcerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response:a pilot study. Pharmacol Res. 2008 Nov-Dec;58(5-6):344-7.267. NIMHResearchDomainCriteria(RDoC).https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml268.
O’Neil A., Quirk S.E., Housden S.L. et al. The relationship between diet andmental health in children and adolescents: a systematic review // Am. J. PublicHealth. 2014. Vol. 104. P. e31–e42.269. O'Brien FE, Dinan TG, Griffin BT, Cryan JF. Interactions betweenantidepressants and P-glycoprotein at the blood–brain barrier: clinical significanceof in vitro and in vivo findings. Br J Pharmacol. 2012 January; 165(2): 289–312.270.
Odgerel Z, Talati A, Hamilton S P, Levinson D F, Weissman M M.Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 inEuropean- and African-American subjects from the National Institute of MentalHealth's Collaborative Center for Genomic Studies. Transl Psychiatry. 2013September; 3(9): e307271. Olfson M, Marcus S, Tedeschi M: Continuity of antidepressant treatment foradults with depression in the United States. Am J Psychiatry 2006, 163:101–108.289272. Olfson M, Marcus SC (2009) National patterns in antidepressantmedication treatment. Arch Gen Psychiatry 66(8):848–856273. Papakostas G I, Fava M, Dialogues ClinNeurosci. 2008 Dec; 10(4): 439–451.274. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV et al.Ziprasidone augmentation of escitalopram for major depressive disorder: efficacyresults from a randomized, double-blind, placebo-controlled study.
Am JPsychiatry 2015; 172: 1251–1258.275. Papakostas GI, Iosifescu DV, Renshaw PF, et al. Brain MRI white matterhyperintensities, cardiovascular risk factors, and one-carbon cycle metabolism innon-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res:Neuroimag. 2005;140:301-307.276. Papakostas GI, McGrath PJ, Stewart J, et al. Psychic and somatic anxietysymptoms as predictors of response to fluoxetine in major depressive disorder.Psychiatry Res. 2008;161:116-120.277.
Papakostas GI, Petersen T, Iosifescu DV, Alpert JE, Nierenberg AA, FavaM. Somatic symptoms as predictors of time to onset of response to fluoxetine inmajor depressive disorder. J Clin Psychiatry. 62004;5:543-546.278. Papakostas GI, Petersen T, Iosifescu DV, et al. Axis III co-morbidity intreatment-resistant depression. Psychiatry Res. 2003;118:183-188.279. Papakostas GI, Petersen T, Iosifescu DV, et al.
Obesity among outpatientswith major depressive disorder. Int J Neuropsychopharmacol. 2004; 7:1-5.280. Papakostas GI, Petersen T, Lebowitz BD, et al. The relationship betweenserum folate, vitamin B12 and homocysteine levels in major depressive disorderand the timing of clinical improvement to fluoxetine.
Int J Neuropsychopharmacol.2005;8:523-528.281. Papakostas GI, Petersen T, Pava J, et al. Hopelessness as a predictor of nonresponse to fluoxetine in major depressive disorder. Ann Clin Psychiatry.2007;19:5-8.282. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ.Higher 5-HT1A receptor binding potential during a major depressive episodepredicts poor treatment response: preliminary data from a naturalistic study.Neuropsychopharmacology. 2006 Aug;31(8):1745-9. Epub 2006 Jan 4.283.
Patience DA, McGuire RJ, Scott AI, Freeman CP. The Edinburgh PrimaryCare Depression Study: personality disorder and outcome. Br J Psychiatry.1995;167:324-330.284. Patten SB, Wang JL, Williams JV, et al. Descriptive epidemiology of majordepression in Canada. Can J Psychiatry 2006;51:84–90.290285. Paykel, E. S.
(2003). Life events and affective disorders. Acta psychiatricaScandinavica. Supplementum, 108(418), 61–6.286. Petersen T, Papakostas GI, Bottonari K, et al. NEO-FFI factor scores aspredictors of response to fluoxetine treatment in depressed outpatients. PsychiatryRes.
2002;109:9-16.287. Pettit JW, Lewinsohn PM, Joiner TE Jr. Propagation of major depressivedisorder: relationship between first episode symptoms and recurrence. PsychiatryRes 2006;141:271–8.288. Phillips M.R. Will RDoC hasten the decline of America’s global leadershiprole in mental health? // World Psychiatry. 2014. Vol. 13. P. 40–41.289. Piccinelli, M. (2000). Gender differences in depression: Critical review. TheBritish Journal of Psychiatry, 177(6), 486–492.290. Pigott HE, Leventhal AM, Alter GS, Boren JJ. Efficacy and effectiveness ofantidepressants: current status of research.
Psychother Psychosom.2010;79(5):267-79.291. Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, MalhotraAK, Gu HH, Sadee W. Dopamine transporter gene variant affecting expression inhuman brain is associated with bipolar disorder.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
